Vaccines have changed modern medicine, leading to a 99 percent decline in the incidence of more than a dozen potentially deadly diseases. And the innovations keep coming. Now, in addition to a ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last year. There are currently no approved vaccines to protect against ...